Picture Berlin Partner Hotspot for Startups 650x80px
Document › Details

Breath Therapeutics B.V.. (10/17/18). "Press Release: Breath Therapeutics Appoints Peter Shadday as Chief Commercial Officer". Munich.

Organisations Organisation Breath Therapeutics B.V.
  Group Zambon (Group)
  Organisation 2 Vertex Pharmaceuticals Inc. (Nasdaq: VRTX)
  Group Vertex Pharmaceuticals (Group)
Products Product L-CsA (inhaled Liposomal Cyclosporine A)
  Product 2 respiratory drug delivery technology
Persons Person Shadday, Peter (Breath Therapeutics 201810– CCO before Vertex + Lundbeck + Gilead + Novartis)
  Person 2 Stegemann, Jens (Breath Therapeutics 201609– CEO)

> Peter Shadday adds senior global commercial expertise for strategic and operational marketing and global pharma product launches to the executive management team

> Breath Therapeutics is targeting Bronchiolitis Obliterans with their first molecule L-CsA, a Phase 3 clinical trial ready asset

Breath Therapeutics B.V. (Breath), a private company developing advanced drug-aerosol therapeutics in pulmonary orphan indications, announced today the appointment of Peter Shadday as Chief Commercial Officer. He joins the executive management team and will lead Breath’s activities related to market access and product commercialization.

Peter Shadday brings to Breath more than 20 years of global, senior commercial experience in strategic and operational marketing, plus sales functions with leadership roles in the US, EU, Latin America and Asia Pacific. His international experience provides him with a unique knowledge of different markets and drug-device combinations in orphan disease indications. Additionally, Mr. Shadday has the proven ability to create value in leading global brands and the execution of launch plans.

Dr. Jens Stegemann, Chief Executive Officer of Breath Therapeutics, stated: “With Peter´s experience and track record of global product launches he is the perfect addition to our management team at exactly the correct time, importantly his experience includes consistent best-in-class launch uptakes. We expect our lead program with inhaled Liposomal Cyclosporine A (L-CsA) for the treatment of Bronchiolitis Obliterans (BO) will start Phase 3 clinical trials from early 2019 in the US and Europe. At this stage, we will begin to prepare and implement a thoroughly studied market access strategy in order to assure the future commercial success of L-CsA in all key markets”.

Peter Shadday said: “Breath Therapeutics is uniquely suited to develop drug-aerosol therapeutics in pulmonary orphan indications and I am very much looking forward to joining this dynamic expert team. The Company´s lead drug, L-CsA, is a first-in-class therapy for a true unmet medical need in respiratory medicine. This is an outstanding opportunity to bring this drug to market and significantly improve treatment options for patients.”

Prior to joining Breath, Mr. Shadday was global marketing lead at Vertex for the next generation corrector programs for the treatment of Cystic Fibrosis (CF). Before this time, Mr. Shadday was Vice President and Global Business leader at Lundbeck, successfully leading the global product launch of Brintellix/Trintellix, a novel antidepressant and key brand. Previous to this, at Gilead Sciences, he held the positions of Director of International and Global Commercial Strategy. As International Commercial Strategy lead, he was responsible for the hepatitis B, anti-fungal and respiratory therapeutic franchises. He was also in charge of the global commercial launch of Viread for Hepatitis B, leading the US and International commercial launch teams for the US and International markets. Prior to Gilead, Mr. Shadday held several commercial positions with Novartis in Europe, the US and South America. Mr. Shadday is a dual French and US citizen, with a B.A. of Economics from Yale University and a graduate of the École Supérieure de Commerce Paris (ESCP).

About Bronchiolitis Obliterans (BO)

Bronchiolitis Obliterans (BO) is a severe progressive orphan disease of the bronchioles of the lung that leads to death from respiratory failure. BO is the leading cause of loss of transplanted lungs. Of more than 25 000 people currently living with a lung transplant, approximately half will die within the next five years, mainly related to BO. BO also occurs in patients following allogeneic hematopoietic stem cell transplant, autoimmune disease and some environmental exposures.

About Breath Therapeutics

Breath is a clinical stage biopharmaceutical company specializing in advanced and first-in-class inhalation therapies for severe respiratory diseases with high unmet medical need. For its clinical development, the Company is using new proprietary drug formulations optimized for inhaled administration with exclusively licensed, high performance nebulizers. Breath is focusing on integrated therapy solutions in the interaction between diagnostics, therapeutics and eHealth therapy monitoring.

Breath´s lead development program BOSTON is addressing the treatment of BO with a proprietary formulation of liposomal cyclosporine for inhalation. With proceeds from a USD 46 million Series A financing by top-tier European investors Sofinnova Partners, Gimv and Gilde Healthcare, the Company is currently initiating Phase 3 studies in the US and Europe. PARI Pharma, a worldwide leading nebulizer company, is a strategic development partner and licensor for the PARI eFlow® nebulizer technology for Breath’s BOSTON program.

Breath Therapeutics is Germany and US based with offices in Frankfurt, Munich and Menlo Park, CA.


Breath Therapeutics B.V.
Dr. Jens Stegemann, CEO

Record changed: 2019-07-29


Picture EBD Group Global Partnering Four Events One Price 650x80

More documents for Zambon (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture [iito] Back into Ad 650x80px

» top